Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Robert Smith's research focuses on evaluating the genotoxic potential of various substances and developing improved methodologies for detecting chromosomal damage. He has investigated the in vivo genotoxic potential of smoke flavoring products and compared the efficacy of different concentrations of media for detecting chromosomal damage in vitro and micronuclei in vivo. Smith has also explored the inclusion of recovery periods in lymphocyte micronucleus assays to account for cell cycle delays without compromising sensitivity. His work extends to infectious disease research, with publications on malaria growth and immune correlates following vaccination, and clinical trials for multiple myeloma, including long-term follow-up studies. Smith holds an h-index of 19 with 50 publications and 1,390 citations. He has collaborated with Fenghuang Zhan, Guido Tricot, John D. Shaughnessy, and Eric R. Siegel at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 19
- Publications: 50
- Citations: 1,390
Selected Publications
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
Collaboration Network
Top Collaborators
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Similar Researchers
Based on overlapping research topics